Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Consensus Rating of “Buy” from Brokerages

Shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) have earned a consensus recommendation of “Buy” from the ten research firms that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and three have issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have covered the stock in the last year is $32.8750.

TEVA has been the topic of a number of research reports. UBS Group upped their price target on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the stock a “buy” rating in a research note on Wednesday, September 24th. Barclays initiated coverage on Teva Pharmaceutical Industries in a research report on Tuesday, December 9th. They set an “overweight” rating and a $35.00 target price on the stock. Scotiabank assumed coverage on Teva Pharmaceutical Industries in a report on Friday, December 5th. They issued a “sector outperform” rating and a $35.00 target price on the stock. JPMorgan Chase & Co. boosted their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Finally, Piper Sandler upped their price objective on shares of Teva Pharmaceutical Industries from $30.00 to $40.00 and gave the stock an “overweight” rating in a report on Monday, December 22nd.

Teva Pharmaceutical Industries Trading Down 0.9%

NYSE:TEVA opened at $30.94 on Monday. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 2.31. The stock has a market capitalization of $35.48 billion, a price-to-earnings ratio of 51.56, a PEG ratio of 1.79 and a beta of 0.66. The firm has a fifty day simple moving average of $26.84 and a two-hundred day simple moving average of $21.07. Teva Pharmaceutical Industries has a 12 month low of $12.47 and a 12 month high of $31.99.

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, CAO Amir Weiss sold 12,300 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The shares were sold at an average price of $30.20, for a total value of $371,460.00. Following the transaction, the chief accounting officer owned 5,650 shares of the company’s stock, valued at approximately $170,630. This trade represents a 68.52% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Roberto Mignone sold 77,400 shares of the company’s stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $30.24, for a total value of $2,340,576.00. Following the sale, the director owned 367,600 shares of the company’s stock, valued at $11,116,224. This trade represents a 17.39% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 622,060 shares of company stock worth $17,076,965. 0.55% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Advisors Asset Management Inc. purchased a new position in Teva Pharmaceutical Industries in the second quarter valued at about $41,000. Cromwell Holdings LLC grew its holdings in Teva Pharmaceutical Industries by 40.3% during the third quarter. Cromwell Holdings LLC now owns 2,191 shares of the company’s stock valued at $44,000 after purchasing an additional 629 shares during the period. Sound Income Strategies LLC increased its position in Teva Pharmaceutical Industries by 3,715.8% in the second quarter. Sound Income Strategies LLC now owns 2,900 shares of the company’s stock worth $49,000 after buying an additional 2,824 shares during the last quarter. MAI Capital Management raised its stake in shares of Teva Pharmaceutical Industries by 26.8% in the second quarter. MAI Capital Management now owns 3,293 shares of the company’s stock valued at $55,000 after buying an additional 697 shares during the period. Finally, Rothschild Investment LLC raised its stake in shares of Teva Pharmaceutical Industries by 97.0% in the third quarter. Rothschild Investment LLC now owns 2,738 shares of the company’s stock valued at $55,000 after buying an additional 1,348 shares during the period. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.